TNFSF15 and atherosclerosis: Given the elevated TL1A levels in the peripheral blood and plaque phenotypes of atherosclerosis patients, along with its dual effects on macrophage-derived and SMC-derived foam cells, TL1A emerges as a promising biomarker and therapeutic target.